Phoenix Bio



Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

    Teraoka, Y. Uchida, T. Imamura, M. Osawa, M. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

    Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157.

    Inhibitory effects of drugs on the metabolic activity of mouse and human aldehyde oxidases and influence on drug-drug interactions

      Takaoka, N. Sanoh, S. Okuda, K. Kotake, Y. Sugahara, G. Yanagi, A. Ishida, Y. Tateno, C. Tayama, Y. Sugihara, K. Kitamura, S. Kurosaki, M. Terao, M. Garattini, E. Ohta, S.

      Biochem Pharmacol. 2018 Apr 17;154:28-38.

      FXR Activation by Obeticholic Acid or Non-Steroidal Agonists Induces a Human-Like Lipoprotein Cholesterol Change in Mice with Humanized Chimeric Liver

        Papazyan, R. Liu, X. Liu, J. Dong, B. Plummer, E. M. Lewis, R. D., 2nd Roth, J. D. Young, M. A.

        J Lipid Res. 2018 Mar 20. pii: jlr.M081935. doi: 10.1194/jlr.M081935.

        Acute HBV infection in humanized chimeric mice has multiphasic viral kinetics

          Ishida, Y. Chung, T. L. Imamura, M. Hiraga, N. Sen, S. Yokomichi, H. Tateno, C. Canini, L. Perelson, A. S. Uprichard, S. L. Dahari, H. Chayama, K.

          Hepatology. 2018 Mar 23. doi: 10.1002/hep.29891.

          Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

            Rolt, A. Le, D. Hu, Z. Wang, A. Q. Shah, P. Singleton, M. Hughes, E. Dulcey, A. E.He, S. Imamura, M. Uchida, T. Chayama, K. Xu, X. Marugan, J. J. Liang, T. J.

            J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093/infdis/jiy039.

            A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage

              Reddy, B. U. Mullick, R. Kumar, A. Sharma, G. Bag, P. Roy, C. L. Sudha, G. Tandon, H. Dave, P. Shukla, A. Srinivasan, P. Nandhitha, M.Srinivasan, N. Das, S.

              Antiviral Res. 2017 Dec 7;150:47-59.

              Hepatitis C replication inhibitors that target the viral NS4B protein

                Miller, J. F. Chong, P. Y. Shotwell, J. B. Catalano, J. G. Tai, V. W. Fang, J. Banka, A. L. Roberts, C. D. Youngman, M. Zhang, H. Xiong, Z. Mathis, A. Pouliot, J. J. Hamatake, R. K. Price, D. J. Seal, J. W., 3rd Stroup, L. L. Creech, K. L. Carballo, L. H. Todd, D. Spaltenstein, A. Furst, S. Hong, Z. Peat, A. J.

                J Med Chem. 2014 Mar 13;57(5):2107-20

                Significance of aldehyde oxidase during drug development: Effects on drug metabolism, pharmacokinetics, toxicity, and efficacy

                  Sanoh, S. Tayama, Y. Sugihara, K. Kitamura, S. Ohta, S.

                  Drug Metab Pharmacokinet. 2015 Feb;30(1):52-63.

                  A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression

                    Mueller, H. Wildum, S. Luangsay, S. Walther, J. Lopez, A. Tropberger, P. Ottaviani, G. Lu, W. John Parrott, N. Zhang, J. D. Schmucki, R. Racek, T. Hoflack, J. C. Kueng, E. Point, F. Zhou, X. Steiner, G. Lutgehetmann, M. Rapp, G. Volz, T. Dandri, M. Yang, S. Young, J. A. T. Javanbakht, H.

                    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393-0. doi: 10.1016/j.jhep.2017.10.014.

                    Efficacy of NVR 3-778, Alone and in Combination With Pegylated Interferon, vs Entecavir in uPA/SCID Mice With Humanized Livers and HBV Infection

                      Klumpp, K. Shimada, T. Allweiss, L. Volz, T. Lutgehetmann, M. Hartman, G. Flores, O. A. Lam, A. M. Dandri, M.

                      Gastroenterology. 2017 Oct 24. pii: S0016-5085(17)36276-5. doi: 10.1053/j.gastro.2017.10.017.

                      Candidate genes responsible for early key events of phenobarbital-promoted mouse hepatocellular tumorigenesis based on differentiation of regulating genes between wild type mice and humanized chimeric mice

                        Ohara A , Takahashi Y,  Kondo  M,  Okuda Y, Takeda  S,  Kushida M, Kobayashi  K,  Sumida K, Yamada T

                        Toxicol Res. 2017; 6(6): 795-813

                        Evaluation of the human relevance of the constitutive androstane receptor-mediated mode of action for rat hepatocellular tumor formation by the synthetic pyrethroid momfluorothrin

                          Okuda, Y. Kushida, M. Kikumoto, H. Nakamura, Y. Higuchi, H. Kawamura, S. Cohen, S. M. Lake, B. G.Yamada, T.

                          J Toxicol Sci. 2017;42(6):773-788. doi: 10.2131/jts.42.773.

                          Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus

                            Sato, Y. Matsui, H. Yamamoto, N. Sato, R. Munakata, T. Kohara, M. Harashima, H.

                            J Control Release. 2017 Oct 3;266:216-225. doi: 10.1016/j.jconrel.2017.09.044.

                            Organic anion transporting polypeptides (OATPs)-mediated drug-drug interaction study between rosuvastatin and cyclosporine A in chimeric mice with humanized liver

                              Uchida, M. Tajima, Y. Kakuni, M. Kageyama, Y. Okada, T. Sakudara, E. Tateno, C. Hayashi, R.

                              Drug Metab Dispos. 2017 Oct 19. pii: dmd.117.075994. doi: 10.1124/dmd.117.075994.

                              Assessment of amiodarone-induced phospholipidosis in chimeric mice with a humanized liver

                                Sanoh, S. Yamachika, Y. Tamura, Y. Kotake, Y. Yoshizane, Y. Ishida, Y. Tateno, C. Ohta, S.

                                J Toxicol Sci. 2017;42(5):589-596. doi: 10.2131/jts.42.589.

                                Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus

                                  Hamana, A. Takahashi, Y. Uchida, T. Nishikawa, M. Imamura, M. Chayama, K. Takakura, Y.

                                  Antiviral Res. 2017 Aug 31;146:130-138.

                                  Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages

                                    Cheng, X. Xia, Y. Serti, E. Block, P. D. Chung, M. Chayama, K. Rehermann, B. Liang, T. J.

                                    Hepatology. 2017 Jun 30. doi: 10.1002/hep.29348.

                                    Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus

                                      Tsuge, M. Uchida, T. Hiraga, N. Kan, H. Makokha, G. N. Abe-Chayama, H. Miki, D. Imamura, M. Ochi, H. Hayes, C. N. Shimozono, R. Iwamura, T.Narumi, H. Suzuki, T  Kainoh, M. Taniguchi, T.

                                      Antimicrob Agents Chemother. 2017 May 24;61(6).

                                      Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells

                                        Chida, T. Ito, M. Nakashima, K. Kanegae, Y. Aoshima, T. Takabayashi, S. Kawata, K. Nakagawa, Y. Yamamoto, M. Shimano, H. Matsuura, T. Kobayashi, Y. Suda, T. Suzuki, T.

                                        Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.

                                        The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection

                                          Niu, C. Livingston, C. M. Li, L. Beran, R. K. Daffis, S. Ramakrishnan, D. Burdette, D. Peiser, L. Salas, E. Ramos, H. Yu, M. Cheng, G. Strubin, M. Delaney Iv, W. E. Fletcher, S. P.

                                          PLoS One. 2017 Jan 17;12(1):e0169648.